Clinical trial support
BostonGene provides extensive support for clinical trials, ensuring compliance with regulatory standards. From prospective patient selection to treatment response monitoring and adverse event prediction, BostonGene addresses the needs of precision oncology trials in all aspects.
Patient identification for clinical trials
CLIA-certified and CAP-accredited platforms ensure that the trial population is well-defined and representative of the targeted patient population:
Learn more
- Whole exome sequencing (WES)
- Whole transcriptome sequencing (WTS)
- Liquid biopsy – ctDNA
- Immunohistochemistry (IHC)
- Flow cytometry
BostonGene was recognized as the Designated Laboratory
for the ComboMATCH Precision Medicine Clinical Trials
for the ComboMATCH Precision Medicine Clinical Trials
Progress monitoring
Assessing effectiveness while monitoring side effects.
Early response monitoring
Advanced molecular profiling technologies, including non-invasive liquid biopsy solutions, enable timely intervention and therapy optimization through:
- Monitoring changes at the molecular level preceding clinical response.
- Identifying potential resistance mechanisms.
Immune-related adverse event prediction
Immunoprofiling technology captures immune system changes preceding the development of immune-related adverse events (irAE):
- Categorizing patients into risk groups for severe irAEs.
- Identifying immune-modulating treatment options to alleviate the severe complications of irAEs.
Case example: Target population discovery
Pharma challenge
Repeated tissue biopsies for dynamic patient monitoring during clinical trials are often not feasible due to their invasive nature, associated risks for patients with advanced disease and limitations posed by certain tumor locations (e.g., brain).
BostonGene approach
Developed an AI-driven multimodal engine capable of generating pathology images from blood-based cell-free RNA profiling.
Result
Established a “tissue from blood” diagnostic approach to analyze the intratumoral tissue properties using a cell-free RNA assay, achieving a preliminary accuracy of 80%.
This innovative method enables real-time, non-invasive monitoring of disease progression during clinical trials, allowing for adaptive trial strategies to optimize outcomes.
Repeated tissue biopsies for dynamic patient monitoring during clinical trials are often not feasible due to their invasive nature, associated risks for patients with advanced disease and limitations posed by certain tumor locations (e.g., brain).
BostonGene approach
Developed an AI-driven multimodal engine capable of generating pathology images from blood-based cell-free RNA profiling.
Result
Established a “tissue from blood” diagnostic approach to analyze the intratumoral tissue properties using a cell-free RNA assay, achieving a preliminary accuracy of 80%.
This innovative method enables real-time, non-invasive monitoring of disease progression during clinical trials, allowing for adaptive trial strategies to optimize outcomes.
.webp)
